Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Transplantation and Cellular Therapy|May 13, 2026
Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis of PrevalenceMuhammad Kashif Amin, Nabeeha Noor, Muhammad Talha Maqsood, et al.
JACC. Case Reports|May 9, 2025
Pembrolizumab-Induced Smoldering Myocarditis in Patients With Triple-Negative Breast CancerAdnan Shaaban, Alma Habib, Dionisia Quiroga, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal ImpairmentAlma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, et al.
Cancers|November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed IntervalsJordan Snyder, Shebli Atrash, Barry Paul, et al.
Journal for Immunotherapy of Cancer|February 22, 2024
Cardiovascular toxicities associated with bispecific T-cell engager therapyAhmed Sayed, Malak Munir, Sanam M Ghazi, et al.
The American Journal of Tropical Medicine and Hygiene|October 11, 2021
Global Health Education during the COVID-19 Pandemic: Challenges, Adaptations, and Lessons LearnedKristina M Krohn, Michael A Sundberg, Nasreen S Quadri, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 26, 2025
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 TrialIshita Kamboj, Alma Habib, Darryl Chang, et al.
Cancers|March 14, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC GroupMaha Hameed, Alma Habib, Abdullah Mohammad Khan, et al.
JACC. Cardiooncology|November 16, 2023
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art ReviewCooper Quartermaine, Sanam M Ghazi, Aneeq Yasin, et al.
American Journal of Hematology|December 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell LymphomaSwetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, et al.
Pageof 3